glp-1-based therapies Expanding applications of based on GLP1 Timeline of GLP-1 discovery and

Neuroimage (2018) 171:26876

There is no confirmed approval date

Ongoing research explores new formulations (oral, transdermal), longer-acting versions, combinations with other drug classes, expanded indications (heart failure, kidney disease, neurodegenerative conditions), and personalized medicine approaches identifying which patients benefit most

For example, in the lungs, GLP-1s may reduce the inflammatory response, improve oxidative stress, regulate protease/anti-protease imbalance, improve airway mucus homeostasis and reduce airway remodeling to provide benefit in patients with COPD

These foods can help to reduce nausea temporarily but having too much can work against weight loss

Sirt1 deficiency, by regulating Wnt/-catenin activity increases the proliferation of EEC progenitors and subsequently increases the number of EECs, including L-cells in HFD-fed mice and the organoid culture system